Resonance Health Ltd · ASX:RHT

Resonance Health — Shareholder Meeting (November 2014)

18 slides from Resonance Health's shareholder meeting presentation, Nov 27, 2014

1. Slide 1: Annual General Meeting 27th November 2014

   ASX: RHT Resonance Health Limited For personal use only ASX: RHT Annual General Meeting 27th November 2014

2. Slide 2: Resonance Health Limited

   Resonance Health Limited ___________________________________________________________________________________________  ASX Listed: RHT For personal use only  RHT develops patent-protected medical image analysis software for the assessment of various liver disease conditions o RHT provides image ana

3. Slide 3: Products / Pipeline

   Products / Pipeline _______________________________________________________________________________________________________ For personal use only Products / Pipeline FerriScan® Cardiac T2* HepaFat- Fibrosis Other Scan® •Iron overload •Cardiac iron •Liver fibrosis • Opportunities •Fatty liver measure

4. Slide 4: Year in Review

   Year in Review ASX: RHT ___________________________________________________________________________________________ For personal use only  50% increase in sales revenue year on year  50+ new radiology facilities starting using FerriScan during the year  33% increase in the number of referring cli

5. Slide 5: Strong growth year on year

   Strong growth year on year _________________________________________________________________________________________________ For personal use only • 32% increase in volume • Over 5,500 image analyses performed during FY 2013/14 Double digit annual Annual Image Analysis Volumes growth in 6000 volumes

6. Slide 6: Services Business Unit

   Services Business Unit _________________________________________________________________________________________________  50% increase in revenue (AU$2.3m) For personal use only o Image analysis services o Clinical trial project management services  50+ new MRI facilities providing FerriScan® o Fe

7. Slide 7: Global Access to FerriScan

   Global Access to FerriScan _________________________________________________________________________________________________ For personal use only Some FerriScan® locations, 250+ have been activated

8. Slide 8: HepaFat-Scan

   HepaFat-Scan® _______________________________________________________________________________________________ For personal use only  New product launched in 2014  Provides a measurement of the % of the liver that is fat  FDA, TGA and CE Mark cleared for marketing  Patent application lodged  Com

9. Slide 9: Non-alcoholic fatty liver disease

   Non-alcoholic fatty liver disease _______________________________________________________________________________________________ • Epidemic in many western and developing countries with significant For personal use only health implications Fatty Fibrosis & Liver Obesity Liver Inflammation Cirrhosis

10. Slide 10: HepaFat-Scan

    HepaFat-Scan® _______________________________________________________________________________________________ • Current diagnostics are invasive (liver biopsy) or don’t measure the For personal use only amount of fat in the liver (ultrasound) • HepaFat-Scan provides a measurement of the fraction of

11. Slide 11: Liver Fibrosis Pipeline Project

    Liver Fibrosis Pipeline Project _________________________________________________________________________________________________ • Pipeline product in development to measure liver fibrosis using MRI For personal use only imaging • Collaborating with the University of Western Australia and other res

12. Slide 12: Summary

    Summary _________________________________________________________________________________________________  Strong growth in FerriScan sales volumes For personal use only  Strong growth in revenue  Significant increase in number of FerriScan sites  Partnerships with pharmaceutical companies enabl

13. Slide 13: End of presentation

    For personal use only End of presentation

14. Slide 14: Resolutions

    For personal use only Resolutions

15. Slide 15: Proxy Results: Remuneration Report

    Proxy Results Resolution 1 For personal use only Adoption of the Remuneration Report For Against Abstaining Discretionary 31,488,418 1,532,573 73,480,734 205,226

16. Slide 16: Proxy Results: Re-election of Director

    Proxy Results Resolution 2 For personal use only Re-election of Mr Simon Panton as a Director For Against Abstaining Discretionary 105,950,167 550,000 1,558 205,226

17. Slide 17: Proxy Results: Employee Share Plan

    Proxy Results Resolution 3 For personal use only Adoption of Employee Share Plan For Against Abstaining Discretionary 101,590,412 4,916,005 1,558 198,976

18. Slide 18: Close of meeting

    For personal use only Close of meeting

Resonance Health — Shareholder Meeting (November 2014) on 6ix